Press release
Immune Checkpoint Inhibitors Market Size By 2026 | Top Key Players are AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, and Sanofi, among others. Companies such as Novartis AG
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/20122
Expanding at a booming CAGR of 14.6%, the global market for immune checkpoint inhibitors market is expected to reach a value beyond US$ 35 Bn over 2018-2026. Growing prevalence of various types of cancers and expanding healthcare expenditure will remain the most prominent drivers of immune checkpoint inhibitors market over the forecast period. Besides cancer prevalence, increasing FDA approvals and growing use of immune-oncology products in treating cancers will also push the demand for immune checkpoint inhibitors in the near future. However, high price point associated with both drug development and treatment will continue to restrict adoption. Frequently observed last stage failure will also remain a major concern in the long run.
“Our extensive company share analysis predicts that the top two players in the global immune checkpoint inhibitors market currently hold a massive revenue share of over 95%. Based on the exhaustive assessment of each drug class in the global immune checkpoint inhibitors market, we arrived at the forecast that the PD-1 will continue dominance in the market, primarily attributed to rapid FDA approvals to PD-1 products,” explained an expert senior research analyst working with the healthcare and life sciences domain at Persistence Market Research.
FDA Approvals Continue to Encourage North American Market for Immune Checkpoint Inhibitors
North America is likely to continue monopoly in the global market for immune checkpoint inhibitors with over 65% share of the total market revenue. Large number of FDA approvals, expanding application base in treatments for various cancer types, and increasing combination drug approvals will play a pivotal role in shaping the market for immune checkpoint inhibitors in North America. According to PMR’s regional analysis of global immune checkpoint inhibitors market, Asia Pacific will demonstrate vigorous growth throughout the projection period – at the double digit CAGR of over 17%.
Request for Report Methodology @: https://www.persistencemarketresearch.com/methodology/20122
High Potential Combination Therapies to Open New Doors of Opportunities
With a strong reference post success of the promising results delivered by Bristol-Myers Squibb using a combination of Yervoy and Opdivo, the market for immune checkpoint inhibitors has been witnessing several more combination therapy products in the pipeline. Such a scenario is responsible for the current situation of the immune checkpoint inhibitors marketplace that reflects a major paradigm shift of companies from conventional mono-therapies to combination therapies for better end results. While a considerable number of combination therapies introduced by various companies have been successfully contributing to the efforts in transforming oncology, the global market for immune checkpoint expects successful introduction of more such therapies. One of those in the pipeline includes the combination with target specific mAbs, chemotherapy, and other checkpoint inhibitors.
Key Players to Invest Efforts in Developing Products to Traverse Diverse Indications
The global immune checkpoint inhibitors market is competitive yet consolidated due to strong presence of established players; however, a few prominent brands such as Tecentriq have strategically maintained a consistent position in the market since their first product launch. A majority of leading players participating in the global immune checkpoint inhibitors marketplace are concentrating on incorporating value addition programs for regulating the customer base through enhancement of product offerings to suit a diverse range of indications.
Get full Report Now: https://www.persistencemarketresearch.com/checkout/20122
Established companies in the global immune checkpoint inhibitors market landscape are striving to enhance therapeutic applications of their existing product offerings. Moreover, a number of key players are also eyeing the high potential markets emerging in developing countries such as KSA and South Africa by seeking FDA approvals to their products in these markets.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Checkpoint Inhibitors Market Size By 2026 | Top Key Players are AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, and Sanofi, among others. Companies such as Novartis AG here
News-ID: 1529955 • Views: …
More Releases from Persistence Market Research (PMR)
Virtual Desktop Infrastructure Market Unit Sales to Witness heightened Growth in …
As per findings of a new market research report by Persistence Market Research, the global virtual desktop infrastructure market reached a valuation of nearly US$ 3.5 Bn in 2019, and is anticipated to exhibit a CAGR of around 12% during the forecast period of 2020 to 2030.The adoption of BYOD allows employees to bring their own devices in the organization, which allows then to access company information and applications via virtual desktop infrastructure. With such a BYOD policy, both, employers…
Physician Scheduling Systems Market to Generate Profitable Avenues for Existing …
As per findings of a new market research report by Persistence Market Research, the global physician scheduling system market reached US$ 311 Mn in 2019 and is anticipated to exhibit a healthy CAGR of 14% during the forecast period of 2020 to 2030. Adoption of physician scheduling systems is increasing across the world, as physicians encounter difficulties with increasing administrative tasks and regulations, which affects their ability to offer patient care, and they struggle to sustain their practices. To combat administrative work…
Demand for Rfid Electronic Toll Collection System Market from Major End-use Sect …
Many toll collection systems have already been developed with RFID technology, which is used to verify the identity of vehicles. RFID technology can provide new capabilities as well as an efficient method to manage, analyze, and collect information of vehicles at toll plazas. RFID electronic toll collection lanes reduce the traffic at toll booths. Increasing number of RFID lane systems, resulting in increased demand for integration, support services, and maintenance,…
Smart Home Cloud Platform Market Unit Sales to Witness heightened Growth in the …
In a smart home, appliances such as ACs, TVs, geysers, and lights have the potential to communicate with a cloud server. The cloud server communicates with these smart devices by sending and receiving signals through smartphones, laptops, or voice-enabled digital assistant devices.A homeowner can make his/her existing home smart by integrating cloud-based technology with it. Cloud computing enables homeowners to remotely access their home appliances, even if they are miles…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
